Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research-Reference-Cited by-同舟云学术

Embracing Uncertainties Over the Evidence of New Oral Antivirals for COVID‐19: Challenges in Pharmacoepidemiologic Research

Published:2023-01-09 Issue:5 Volume:63 Page:521-525
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharma

Author:

Ferreira da Silva Renato¹²³^ORCID,Silva Ana Marta¹²³^ORCID,Morato Manuela⁴^ORCID,Ribeiro‐Vaz Inês¹²³^ORCID,Polónia Jorge Junqueira¹³⁵^ORCID

Affiliation:

1. Porto Pharmacovigilance Centre Faculty of Medicine of the University of Porto Porto Portugal

2. Department of Community Medicine Health Information and Decision Faculty of Medicine of the University of Porto Portugal

3. CINTESIS – Center for Health Technology and Services Research Porto Portugal

4. LAQV/REQUIMTE Laboratory of Pharmacology Department of Drug Sciences Faculty of Pharmacy of the University of Porto Porto Portugal

5. Department of Medicine Faculty of Medicine of the University of Porto Porto Portugal

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.2195

Reference13 articles.

1. A comprehensive review of adverse events to drugs used in COVID‐19 patients: Recent clinical evidence

2. Drug repurposing strategies for COVID-19

3. European Medicines Agency.Treatments and vaccines for COVID‐19 Share Table of contents: authorised medicines. Accessed November 21 2022.https://www.ema.europa.eu/en/human‐regulatory/overview/public‐health‐threats/coronavirus‐disease‐covid‐19/treatments‐vaccines‐covid‐19

4. European Medicines Agency.EMA endorses use of dexamethasone in COVID‐19 patients on oxygen or mechanical ventilation. Accessed November 21 2022.https://www.ema.europa.eu/en/news/ema‐endorses‐use‐dexamethasone‐covid‐19‐patients‐oxygen‐mechanical‐ventilation

5. European Medicines Agency.Lagevrio ‐ COVID‐19 ‐ Article‐5(3) procedure: conditions of use conditions for distribution and patients targeted and conditions for safety monitoring. Accessed November 21 2022.https://www.ema.europa.eu/en/documents/referral/lagevrio‐also‐known‐molnupiravir‐mk‐4482‐covid‐19‐article‐53‐procedure‐conditions‐use‐conditions_en.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review;Drug Safety;2024-08-19